GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

The average forecast of $111,187 suggests a potential correction or stabilization phase. This range reflects expectations of reduced post-halving momentum and broader market recalibrations.